« Back
Home /
Razoxane

Razoxane

Item no.	HY-119425-5mg
Manufacturer	MedChem Express
CASRN	21416-67-1
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	99.16
Citations	[1]J P Braybrooke, et al. A phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res.2000; 6(12):4697-704. [2]F Wingen, et al. Antimetastatic effects of Razoxane in a rat osteosarcoma model. Clin Exp Metastasis.Jan-Mar 1987; 5(1):9-16.
Smiles	CC(CN(CC(N1)=O)CC1=O)N(CC(N2)=O)CC2=O
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	ICRF 159
Shipping condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Topoisomerase
Shipping Temperature	Blue Ice
Storage Conditions	-20°C, 3 years (Powder)
Molecular Weight	268.27
Product Description	Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1].
Manufacturer - Research Area	Cancer
Solubility	10 mM in DMSO
Manufacturer - Pathway	Cell Cycle/DNA Damage
Isoform	Topo II
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-119425-5mg-safety-datasheet.pdf